Mirati Therapeutics gains on FDA approval for lung cancer drug
12/12/2022 22:46
** Shares of cancer drug developer Mirati Therapeutics Inc
MRTX.O up 8.6% at $45 after market
** The U.S. Food and Drug Administration approved company's
lung cancer drug adagrasib, according to the health regulator's
website urn:newsml:reuters.com:*:nL4N3323D6
** Mirati was seeking approval for the drug for treating
patients with advanced lung cancer who have stopped responding
to other therapies
** YTD, company's shares down 71.7%
(Reporting by Priyamvada C in Bengaluru)
((Priyamvada.c@thomsonreuters.com))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)